Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Bray F .2020 .GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Global cancer statistics, : .
.2021 .. , 10(3) : 209-49.
Abbas G,Shah S,Hanif M,Asghar A,Shafique M,Ashraf K. . .Cancer prevalence, incidence and mortality rates in Pakistan in 2018. , : .
.2020 .. , 10(4) : 517-8.
bulcan. .2019 .. , 12 : .
Zagami P,Carey LA . .Triple negative breast cancer: Pitfalls and progress. 2022 Aug, 20(1) : 95.
Jitariu AA,Cîmpean AM,Ribatti D,Raica M. . .Triple negative breast cancer: the kiss of death. DOI:10, : .
Dass SA,Tan KL,Selva Rajan R,Mokhtar NF,Mohd Adzmi ER,Wan Abdul Rahman WF .2021 .Triple negative breast cancer: A review of present and future diagnostic modalities. Medicina, 10(1) : 62.
Ullah MF .2019 .Breast cancer: current perspectives on the disease status. Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. Breast Can Met Drug Resist, 10(6) : 4-64.
Maennling AE,Tur MK,Niebert M,Klockenbring T,Zeppernick F,Gattenlöhner S .1826 .Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers, 10(12) : .
Talukdar S,Emdad L,Das SK,Fisher PB .2020 .EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res, 04 : 161-88.
Oshi M,Gandhi S,Tokumaru Y,Yan L,Yamada A,Matsuyama R .2021 .Conflicting roles of EGFR expression by subtypes in breast cancer. Am J Cancer Res, 11(10) : 5094.
Zakaria Z,Zulkifle MF,Hasan WA,Azhari AK,Raub SH,Eswaran J .2019 .Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. Onco Targets Ther, 10 : 8-16.
Howard FM,Olopade OI .2021 .Epidemiology of triple-negative breast cancer: a review. Cancer J, 10(1) : 8-16.
Munawar S,Haider R,Ali SM,Yaqeen SR,Islam S,Asghar IA .2021 .Triple-negative metaplastic breast carcinoma: association of epidermal growth factor receptor expression with prognostic parameters and clinical outcome. Cureus, 10(5) : .
Hashmi AA,Naz S,Hashmi SK,Irfan M,Hussain ZF,Khan EY .2019 .Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters. Surg Exp Pathol, 10(1) : 1-7.
Sajid MT,Ahmed M,Azhar M,Mustafa Q,Shukr I .2014 .Age-related frequency of triple negative breast cancer in women. J Coll Physicians Surg Pak, 24(6) : 400-3.
Sikov WM,Berry DA,Perou CM,Singh B,Cirrincione CT,Tolaney SM .2014 .Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-perweek paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Onco, 57(1) : 13.
Jiang W,Wang X,Zhang C,Xue L,Yang L .2020 .Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. Onco Letters, 11274(3) : 1842-8.
Maqbool M,Bekele F,Fekadu G .2022 .Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer Ther, 10 : 15-24.
Uribe ML,Marrocco I,Yarden Y. .2021 .EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers, 10(11) : 2748.
Bianchini G,De Angelis C,Licata L,Gianni L .2022 .Treatment landscape of triple-negative breast cancer-Expanded options, evolving needs. Nat Rev Clin Oncol, 10(2) : 91-113.
Liu Y,Zhou Y,Huang KH,Li Y,Fang X,An L,Wang F,Chen Q,Zhang Y,Shi A,Yu S. .2019 .EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging (Albany NY), 10(23) : 11054.
Lev S. .2020 .Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis. Biochem Spc Trans, 10(2) : 657-65.